Analyst firms · BofA Securities · EDIT

BofA Securities EDIT price target and rating history

Editas Medicine Inc. (EDIT) · Health Care

BofA Securities rates Editas Medicine Inc. (EDIT) Underperform with a $1 price target, as of its latest action on Nov 25, 2024. It has published 3 rating actions on EDIT since September 2022, including 1 upgrade and 1 downgrade. Across 3 firms with a EDIT price target in the last 12 months, the median target is $6.

Current rating
Underperform
Price target
$1
Median target, all firms
$6
Actions on EDIT
3

BofA Securities price target on EDIT

$18$9.50$12023202420252026
BofA Securities price target on EDIT, each point a stated target, September 2022 to November 2024.

Every BofA Securities rating on EDIT

How other firms rate EDIT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Wells FargoOverweight$6Oct 8, 2026
GuggenheimBuy$5Sep 23, 2026
Ladenburg ThalmannBuy$6Aug 18, 2026

Questions about BofA Securities and EDIT

What is BofA Securities's price target for EDIT?
BofA Securities's latest stated price target for Editas Medicine Inc. (EDIT) is $1, from its action on Nov 25, 2024.
What is BofA Securities's rating on EDIT?
BofA Securities rates EDIT Underperform, a bearish rating, as of Nov 25, 2024.
When did BofA Securities last change its view on EDIT?
On Nov 25, 2024, BofA Securities downgrades to Underperform from Buy, price target $13 to $1.
How does BofA Securities's EDIT target compare with other analysts?
Across 3 firms with a EDIT price target in the last 12 months, the median target is $6.

More EDIT rating histories

All BofA Securities ratingsEDIT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.